Growing Prevalence of Cancer Cases Globally Drives Growth of Trifluridine API Market

Trifluridine API market is anticipated to grow at a significant CAGR of 8.7% during the forecast period (2024-2031). The market growth is attributed to increasing demand for treatment of various tumors, including herpes simplex keratitis and colorectal cancer. Developments in treatment methods, legal frameworks, and technology improvements all have an impact on the market's growth. According to the National Center for Biotechnology Information (NCBI), in October 2022, Colorectal cancer (CRC) was the third most common cancer in males and the second most common in females, with approximately 1.9 million new cases and 0.9 million mortalities in 2020 globally. Among the patients diagnosed with CRC, 20.0% have metastatic disease and 40.0% of those treated for localized disease eventually develop systemic recurrence.

Browse the full report description of “Trifluridine API Market Size, Share & Trends Analysis Report by Product Type (Trifluridine API Powder and Trifluridine API Solutions), by Application (Antiviral Drugs, Oncology Drugs, and Others), and by End-User (Pharmaceutical Companies, Contract Manufacturing Organizations (CMOs) and Academic and Research Institutes) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/trifluridine-api-market

Idoxuridine and trifluridine share a structural similarity as fluorinated pyrimidine nucleoside. It is an active antiviral drug found in ophthalmic solutions that is primarily used to treat recurrent epithelial keratitis caused by the herpes simplex virus and primary keratoconjunctivitis. Tipiracil is a nucleoside analog in which the sugar moiety has been replaced by a modified pyrrolidine system. Trifluridine is not transformed into an inactive metabolite by Tipracil. Thymidine phosphorylase inhibition and increased trifluridine bioavailability are the mechanisms underlying this trifluridine protection.

Recent Development

• In August 2023, the US FDA approved trifluridine and tipiracil (LONSURF, Taiho Oncology, Inc.) with bevacizumab, for metastatic Colorectal Cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. The recommended LONSURF dose is 35 mg/m2 orally twice daily with food on days 1 through 5 and days 8 through 12 of each 28-day cycle.

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered- 

o By Product Type

o By Application

o By End-User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Merck KGaA, NATCO PHARMA LTD., Pfizer Inc., Sandoz Group AG, and Taiho Pharmaceutical Co., Ltd. among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Trifluridine API Market Report Segment

By Product Type

• Trifluridine API Powder
• Trifluridine API Solution

By Application

• Antiviral Drugs
• Oncology Drugs
• Other (Scientific Research)

By End-User 

• Pharmaceutical Companies
• Contract Manufacturing Organizations (CMOs)
• Academic and Research Institutes

Global Trifluridine API Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/trifluridine-api-market